...Idec Inc. and Elan Corp.’s Tysabri is more likely to occur the longer patients...leukoencephalopathy, increases after 24 to 36 months of Tysabri therapy, the change in what is known...Administration temporarily suspended sales of Tysabri in 2005 after three cases of the infection... (Page B5, 117 words)Date: Nov 7, 2009

...fatal brain disease linked to their multiple sclerosis drug, Tysabri, jumped to 23 from 13 previously disclosed. European regulators...any additional measures necessary to ensure the safe use of Tysabri.’’ Biogen Idec shares closed at $43... (Page G5, 62 words)Date: Oct 25, 2009

...companies’ multiple sclerosis drug Tysabri. That is twice as many cases as previously...will review the risks and benefits of Tysabri and discuss whether added measures are...Elan, an Irish drug maker that markets Tysabri in Europe, plunged $1.13, or 17... (Page B5, 259 words)By: Robert Weisman|Date: Oct 24, 2009

...sales of its fastest-growing drug, Tysabri. The shares fell after the company told...of 21 analysts surveyed by Bloomberg. Tysabri has been linked to 13 cases of a deadly...research, said in a conference call that Tysabri’s label may change to say that... (Page B9, 807 words)Date: Oct 21, 2009

...participate if the stock moves higher,’’ he said. Demand is increasing for Tysabri, Biogen Idec’s fastest-growing product. Tysabri revenue rose 10 percent in the second quarter, to $1.09 billion, as more patients... (Page B8, 295 words)Date: Sep 30, 2009

WASHINGTON - The drug Tysabri, from Biogen Idec Inc. and Elan PLC, has been linked to 13 cases of a deadly brain disease since it was reintroduced in July... (Page B6, 101 words)Date: Sep 17, 2009

...rights to the multiple sclerosis drug Tysabri. New Brunswick, N.J.-based J...8217;s contract with Biogen over Tysabri. Cambridge, Mass.-based Biogen and Elan jointly market Tysabri, which generated $813 million in 2008... (Page B9, 202 words)Date: Sep 15, 2009

...Biogen on the multiple sclerosis drug Tysabri in allowing J&J to buy a minority...other has an option to buy its rights to Tysabri. Biogen argued that Elan assigned its...purchase of Biogen’s rights to Tysabri if Cambridge, Mass.-based Biogen is... (Page B9, 246 words)By: Thom Weidlich|Date: Sep 4, 2009

...battle over a multiple sclerosis drug, Tysabri. The drug “has blockbuster...Biogen’s 50 percent stake of Tysabri, should the Cambridge biotech’...Elan could give it enough control over Tysabri to drive away competitors if it makes... (Page B5, 405 words)By: Sean Sposito|Date: Aug 7, 2009

...million, or 49 cents per share, vs. $206.6 million, or 70 cents per share, a year ago. Avonex sales rose 12 percent and Tysabri sales rose about 27 percent, both treat MS. Acorda was paid $110 million for overseas rights to an experimental MS drug... (Page G6, 82 words)Date: Jul 19, 2009